Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
Peter Martin(Northwestern University), John P. Leonard(New York University), James Drew(Bristol-Myers Squibb (United States)), Leandro Cerchietti(Cornell University), John L. Reagan(Vanderbilt University), Jeffrey Jones(Corewell Health Butterworth Hospital), María V. Revuelta(Cornell University), Nancy L. Bartlett(Washington University in St. Louis), Julio C. Chávez(Moffitt Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Sonali M. Smith(University of Chicago), Chengqing Wu(Bristol-Myers Squibb (United States)), Erin Mulvey(Cornell University)
Cited by 37
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k